Therapy Name | Paclitaxel + Rebastinib |
Therapy Description |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 11 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
rebastinib | DCC-2036 | BCR-ABL Inhibitor 23 FLT3 Inhibitor 48 TIE2 Inhibitor 1 VEGFR2 Inhibitor 34 | Rebastinib (DCC-2036) inhibits the Bcr-Abl fusion and to a lesser extent, the receptor tyrosine kinases TIE-2, FLT3, and VEGFR2 (PMID: 21481795). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|---|---|---|---|
NCT03601897 | Phase I | Paclitaxel + Rebastinib | A Safety, Tolerability and PK Study of Rebastinib in Patients With Advanced Solid Tumors | Recruiting |
NCT02824575 | Phase I | Paclitaxel + Rebastinib Eribulin + Rebastinib | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | Recruiting |